© 1995 by European Society of Cardiology
Copyright © 1995, European Society of Cardiology
Myocardial Gi
-protein levels in patients with hypertensive cardiac hypertrophy, ischemic heart disease and cardiogenic shock
Klinik Ill für Innere Medizin, Uniuersität zu Köln, Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany
* Corresponding author. Tel. (+49-221) 478-6207; Fax (+49-221) 478-6550.
Objective: Increased inhibitory G-protein 
-subunits (Gi) have been reported to be related to adenylyl cyclase desensitization in the failing human heart. In order to investigate whether this cellular alteration occurs already at the stage of hypertensive cardiac hypertrophy or in catecholamine-refractory cardiogenic shock, Gi levels were studied in myocardial samples from patients with hypertensive cardiac hypertrophy, coronary heart disease without heart failure and from patients with cardiogenic shock on high-dose catecholamine therapy as well as from patients without evidence of heart disease. Methods: Gi was quantified with pertussis-toxin-catalyzed 32P-ADP-ribosylation and with a radioimmunoassay in myocardial samples from patients within 16 h of death. The radioimmunoassay was constructed with recombinant G-protein -subunits (rGi1) from transformed E. coli harbouring the full-length cDNA of Gi1, iodinated peptide 125I-KENLKDCGLF and immunoprecipitating antiserum (MB 1) raised against the synthetic peptide (KENLKDCGLF) in rabbits. Results: Pertussis toxin substrates and immunochemical Gi remained stable up to 80 h following storage at room temperature in myocardium obtained during cardiac transplantation. Gs , adenylyl cyclase, β-adrenoceptors and inhibitory receptors were not stable and could not be determined. Increases in myocardial Gi of 65–82% of both pertussis toxin substrates and immunologically quantified Gi were observed in hypertensive cardiac hypertrophy. Catecholamine therapy in patients who died of catecholamine-refractory shock increased myocardial Gi by 225% compared to myocardium from patients with coronary heart disease without heart failure and without catecholamine therapy or compared to control myocardium. Conclusion: These findings provide evidence than an increase in myocardial Gi-proteins could be of relevance in pathological conditions other than chronic heart failure. Since an increase in Gi levels already occurs in hypertensive cardiac hypertrophy, it could play a role in contributing to the development of contractile dysfunction and heart failure in later stages of the syndrome. Finally, an increase in Gi could be one mechanism contributing to catecholamine refractoriness in shock. This could provide a target for pharmacological treatment in this condition.
KEYWORDS Hypertrophy; Heart failure; Adenylyl cyclase; Hypertension; G-proteins; Signal transduction; Shock; Catecholamines
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Selvetella, E. Hirsch, A. Notte, G. Tarone, and G. Lembo Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence Cardiovasc Res, August 15, 2004; 63(3): 373 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Peterson, H. Ju, J. Hao, M. Panagia, D. C. Chapman, and I. M.C. Dixon Expression of Gi-2{alpha} and Gs{alpha} in myofibroblasts localized to the infarct scar in heart failure due to myocardial infarction Cardiovasc Res, March 1, 1999; 41(3): 575 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Zolk, M. Flesch, G. Nickenig, P. Schnabel, and M. Bohm Alteration of intracellular Ca2+-handling and receptor regulation in hypertensive cardiac hypertrophy: insights from Ren2-transgenic rats Cardiovasc Res, July 1, 1998; 39(1): 242 - 256. [Abstract] [Full Text] [PDF]
|
|